All In Biotech

Drug Trial Radar · NCT04604184

ACTION ON COVID-19: A Study to Test Whether BI 764198 Helps Lung Health of People Hospitalised With COVID-19

BI 764198 Efficacy and Safety in Prevention/Progression of ARDS and ARDS-related Complications Secondary to COVID-19 (ACTION ON COVID-19)

Last checked: Nov 20, 2026Latest source record: Apr 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 133 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

133

Actual

Start

Nov 3, 2020

Primary completion

Mar 24, 2021

Study completion May 31, 2021

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Oct 27, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with COVID-19 infection who are in hospital and receive oxygen. Participants need to be 50 years of age or older and need to be at risk of further worsening of their condition. The purpose of the study is to find out whether a medicine called BI 764198 helps people with COVID-19 infection and breathing problems. BI 764198 may prevent cell death and swelling of the lung tissue and therefore help patients with COVID-19 infection. Participants are put into 2 groups by chance. One group of participants gets BI 764198 capsules and the other group gets placebo capsules. The placebo capsules look exactly like the BI 764198 capsules but do not contain any medicine. Participants take 1 capsule per day. Participants are in the study for about a month. At study end, doctors compare the 2 groups for the number of patients that are alive and do not need mechanical breathing support. During the study, the doctors collect information on any health problems of the participants.

Conditions

  • COVID-19

Interventions

  • BI 764198Drug

    BI 764198

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Patients Alive and Free of Mechanical VentilationTime frame: At Day 29

Locations

25 sites in 6 countries. Site status is shown where the registry gives one.

  • University of California Irvine

    Orange, California

  • Rapides Regional Medical Center

    Alexandria, Louisiana

  • St. Elizabeth's Medical Center

    Boston, Massachusetts

  • Newton-Wellesley Hospital

    Newton, Massachusetts

  • Mercy Health St. Vincent Medical Center

    Toledo, Ohio

  • Providence Regional Medical Center

    Everett, Washington

  • MultiCare Tacoma General Hospital

    Tacoma, Washington

  • Hospital Luxemburgo

    Belo Horizonte, Brazil

  • IPECC - Instituto de Pesquisa Clínica de Campinas

    Campinas, Brazil

  • Hospital Ernesto Dornelles

    Porto Alegre, Brazil

  • Hospital Regional Hans Dieter Schmidt

    Santa Catarina, Brazil

  • Hospital de Base - Fac Med de Sao Jose do Rio Preto

    São José do Rio Preto, Brazil

  • Hospital Padre Alberto Hurtado

    Santiago, Chile

  • Hospital Carlos Van Buren

    Valparaíso, Chile

  • Hospital Cardiologica Aguascalientes

    Aguascalientes, Mexico

  • Hospital General de Culiacán "Dr. Bernardo J. Gastellum"

    Culiacán, Mexico

  • Hospital Universitario Dr Jose Eleuterio Gonzalez

    Monterrey, Mexico

  • Hospital Auxilio Mutuo

    Hato Rey, Puerto Rico

  • Hospital Municipal de San Juan

    Rio Piedras, Puerto Rico

  • Hospital A Coruña

    A Coruña, Spain

  • Hospital General Universitario de Alicante

    Alicante, Spain

  • Hospital Universitario Infanta Leonor

    Madrid, Spain

  • Hospital Clínico San Carlos

    Madrid, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Hospital Son Espases

    Palma de Mallorca, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.